Shortened axi-cel manufacturing drives rapid in vivo expansion and shifts the acute toxicity profile in R/R LBCL
- 16 October 2026
- journal article
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (20) , 7018-7022
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- Reduced Chimeric Antigen Receptor T Cell Expansion Postinfusion Is Associated with Poor Survival in Patients with Large B Cell Lymphoma after Two or More TherapiesTransplantation and Cellular Therapy, 2025
- Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trialNature Medicine, 2022
- Rapid manufacturing of non-activated potent CAR T cellsNature Biomedical Engineering, 2022
- Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapyAnnals of Hematology, 2021
- The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell TherapyTransplantation and Cellular Therapy, 2021
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsTransplantation and Cellular Therapy, 2019
- Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic LeukemiaCancer Discovery, 2018
- Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemiaNature Medicine, 2018
- Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T CellsCancer Discovery, 2017
- Chimeric antigen receptor T-cell therapy — assessment and management of toxicitiesNature Reviews Clinical Oncology, 2017